Arginine methylation dysfunction increased risk of acute coronary syndrome in coronary artery disease population: A case-control study

Medicine (United States)

Volumn 96, Issue 7, 2017, Pages

  Zhang, Shengyu ^a   Zhang, Shuyang ^a   Wang, Hongyun ^a   Wu, Wei ^a   Ye, Yicong ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Acute coronary syndrome; Asymmetric dimethylarginine; Methylation

Indexed keywords

ARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; ORNITHINE; PROTEIN ARGININE METHYLTRANSFERASE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; METHYLATION; MIDDLE AGED; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; THORAX PAIN; AGED; COMPLICATION; METABOLISM; REGRESSION ANALYSIS; RISK FACTOR;

ACUTE CORONARY SYNDROME; AGED; ARGININE; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN-ARGININE N-METHYLTRANSFERASES; REGRESSION ANALYSIS; RISK FACTORS;

EID: 85013672856     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000006074     Document Type: Article

References (32)

1. Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation 2004;109:1813-8.
2. LeeMJ, Han SH, Lee JE, et al. Endothelial dysfunction is associated with major adverse cardiovascular events in peritoneal dialysis patients. Medicine 2014;93:e73.
3. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005;97: e53-9.
4. Lu TM, Ding YA, Lin SJ, et al. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003;24:1912-9.
5. Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003;59:824-33.
6. Willeit P, Freitag DF, Laukkanen JA, et al. Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc 2015;4:e001833.
7. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003;107:149-58.
8. Giugliano RP, Braunwald E. 2004ACC/AHA guideline for the management of patients with STEMI: the implications for clinicians. Nat Clin Pract Cardiovasc Med 2005;2:114-5.
9. Jneid H, Anderson JL, Wright RS, et al. 2012ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60: 645-81.
10. Azar RR, Aoun G, Fram DB, et al. Relation of C-reactive protein to extent and severity of coronary narrowing in patients with stable angina pectoris or abnormal exercise tests. Am J Cardiol 2000;86:205-7.
11. Servillo L, Giovane A, D'Onofrio N, et al. Determination of homoarginine, arginine, NMMA, ADMA, and SDMA in biological samples by HPLC-ESI-mass spectrometry. Int J Mol Sci 2013;14: 20131-8.
12. Vicente FB, Vespa G, Miller A, et al. Quantification of arginine and its methylated derivatives in plasma by high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS). Methods Mol Biol 2016;1378:21-30.
13. Frobert O, Hjortshoj SP, Simonsen U, et al. Methylated arginines in stable and acute patients with coronary artery disease before and after percutaneous revascularization. Int J Cardiol 2008;129:288-91.
14. Krempl TK, Maas R, Sydow K, et al. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 2005;26:1846-51.
15. Loland KH, Bleie O, Borgeraas H, et al. The association between progression of atherosclerosis and the methylated amino acids asymmetric dimethylarginine and trimethyllysine. PLoS One 2013;8: e64774.
16. Castillo L, Chapman TE, Sanchez M, et al. Plasma arginine and citrulline kinetics in adults given adequate and arginine-free diets. Proc Natl Acad Sci U S A 1993;90:7749-53.
17. El-Bassossy HM, El-Fawal R, Fahmy A, et al. Arginase inhibition alleviates hypertension in the metabolic syndrome. Br J Pharmacol 2013;169:693-703.
18. Romero MJ, Platt DH, Tawfik HE, et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 2008; 102:95-102.
19. Erdely A, Kepka-Lenhart D, Salmen R, et al. Systemic changes in arginase and arginine metabolism in a model of atherosclerosis: a comparison of apoE-/-and C57 mice. FASEB J 2007;21: 967.5.
20. VassalleC,Bianchi S, Battaglia D, et al. Elevated levels of oxidative stress as a prognostic predictor of major adverse cardiovascular events in patients with coronary artery disease. J Atheroscler Thromb 2012;19:712-7.
21. Vichova T, Motovska Z. Oxidative stress: predictive marker for coronary artery disease. Exp Clin Cardiol 2013;18:e88-91.
22. Aukrust P, Berge RK, Ueland T, et al. Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol 2001;37:485-91.
23. Wang YG, Xiong X, Chen ZY, et al. Expansion of myeloid-derived suppressor cells in patients with acute coronary syndrome. Cell Physiol Biochem 2015;35:292-304.
24. Bouras G, Deftereos S, Tousoulis D, et al. Asymmetric dimethylarginine (ADMA): a promising biomarker for cardiovascular disease? Curr Top Med Chem 2013;13:180-200.
25. Boger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000;87:99-105.
26. Luo Z, Teerlink T, Griendling K, et al. Angiotensin II and NADPH oxidase increase ADMA in vascular smooth muscle cells. Hypertension 2010;56:498-504.
27. Morales Y, Nitzel DV, Price OM, et al. Redox control of protein arginine methyltransferase 1 (PRMT1) activity. J Biol Chem 2015;290: 14915-26.
28. Bahls M, Friedrich N, Atzler D, et al. L-arginine and SDMA serum concentrations are associated with subclinical atherosclerosis in the study of health in pomerania (SHIP). PLoS One 2015;10:e0131293.
29. Hong D, Gao HC, Wang X, et al. Asymmetric dimethylarginine triggers macrophage apoptosis via the endoplasmic reticulum stress pathway. Mol Cell Biochem 2015;398:31-8.
30. Charytan DM, Cinelli A, Zeisberg EM. Association of circulating angiogenesis inhibitors and asymmetric dimethyl arginine with coronary plaque burden. Fibrogenesis Tissue Repair 2015;8:13.
31. Notsu Y, Yano S, Shibata H, et al. Plasma arginine/ADMA ratio as a sensitive risk marker for atherosclerosis: Shimane CoHRE study. Atherosclerosis 2015;239:61-6.
32. Schulze F, Wesemann R, Schwedhelm E, et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004;42:1377-83.